Hip Arthropathy, Surgical Approach
Conditions
Brief summary
The SuperPATH approach is a minimally invasive approach for total hip arthroplasty. This project randomized patients to the SuperPath versus posterior approach. Outcomes examined included functional, VAS pain, narcotic utilization, perioperative outcomes, and radiographic component positions. Participants were followed for 2 years. The aim was to examine if the SuperPATH approach provided significant advantages over the posterior approach on functional testing or return to work for patients.
Detailed description
Background: The Supercapsular Percutaneously-Assisted Total Hip (SuperPATH) approach is a minimally invasive approach for total hip arthroplasty. It has been reported to show earlier mobilization, better gait kinematics, and short hospital length of stay. Our primary objective was to compare functional tests of timed up and go and timed stair climb preoperatively, at discharge, 2 weeks, and 6 weeks postoperatively. Secondary objectives included the return to function in weeks, Oxford hip scores, visual analog scale, narcotic utilization, perioperative outcomes, and radiographic component positions. Methods: Forty-six patients were randomized into two groups on the surgery day: the SuperPATH group (25 patients) and the Posterior group (20 patients). Outcomes examined included functional, VAS pain, narcotic utilization, perioperative outcomes, and radiographic component positions.
Interventions
PROCEDURESuperpath Approach
This is a minimally invasive surgical approach for THA.
Sponsors
Dr. Gavin Wood
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
superpath approach versus posterior approach
Eligibility
Sex/Gender
ALL
Age
21 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis; * Inflammatory degenerative joint disease including rheumatoid arthritis; * Correction of functional deformity. * Subject is skeletally mature (21 years of age or older); * Subject is a candidate to be implanted with the specified combination of components; * Subject is willing and able to complete required study visits and assessments; * Subject plans to be available through the follow-up visits; * Subject is willing to sign the approved informed consent document. * Subjects with a previous THA in the contralateral hip are eligible for enrollment provided it has been at least 1 year since the contralateral THA and the contralateral THA is asymptomatic and not pending revision. Simultaneous bilateral THA subjects will not be permitted to enroll.
Exclusion criteria
* Subject has overt infection or distant foci of infections; * Subject has rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram; * Subject with inadequate neuromuscular status (e.g. prior paralysis, fusion and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable; * Subject has a neuropathic joints; * Subject has hepatitis or HIV infection; * Subject has a neurological or musculoskeletal disease that may adversely affect gait or weight-bearing; * Subject is currently enrolled in another clinical investigation that could affect the endpoints of this study; * Subject is unwilling or unable to sign the informed consent document; * Subject has documented substance abuse issues; * Subject has a body mass index (BMI) of greater than 40;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional Outcomes TUG | 6 weeks | Timed up and go test |
| Functional Outcomes TSC | 6 weeks | Timed stair climb |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subjective Measure | 3 months | Oxford Hip Score - score from 0 (severe hip arthritis) to 48 (satisfactory joint function) |
| Pain Score | 1 month | Visual Analog Scale - score from 0 (no pain) to 10 (worst pain) |
Countries
Canada
Outcome results
None listed